Hepatitis C treatment response kinetics and impact of baseline predictors.
Artikel i vetenskaplig tidskrift, 2011

Summary.  The optimal duration of treatment for hepatitis C virus (HCV) infections is highly variable but critical for achieving cure (sustained virological response, SVR). We prospectively investigated the impact of age, fibrosis, baseline viraemia and genotype on the early viral kinetics and treatment outcome. Patients treated with peginterferon alfa-2a and ribavirin in standard dosing were included: 49 with genotype 1 treated for 48 weeks and 139 with genotype 2 or 3 treated for 24 weeks. The reduced SVR rates in patients older than 45 years, with severe liver fibrosis or pretreatment viraemia above 400 000 IU/mL were strongly associated with slower second phase declines of HCV RNA. Genotype 2/3 infections responded more rapidly than genotype 1, reaching week 4 negativity (RVR) in 59%vs 22%. We conclude that baseline response predictors such as age, fibrosis and viral load were well reflected by the early viral kinetics as assessed by repeated HCV RNA quantifications. The kinetic patterns and the high relapse rate in genotype 2/3 patients without RVR suggest that this group might benefit from treatment durations longer than 24 weeks.

ribavirin

genotype

hepatitis

pegylated interferon

monitoring

HCV RNA

Författare

Magnus Lindh

Göteborgs universitet

B Arnholm

Södra Älvsborgs Sjukhus (SÄS)

Anders Eilard

NU-sjukvården

Martti Färkkilä

Helsingin Yliopisto

Kristoffer Hellstrand

Göteborgs universitet

Martin Lagging

Göteborgs universitet

Nina Langeland

Helse Bergen Haukeland University Hospital

K Mørch

Helse Bergen Haukeland University Hospital

Staffan Nilsson

Chalmers, Matematiska vetenskaper, Matematisk statistik

Göteborgs universitet

Court Pedersen

Syddansk Universitet

Mads Rauning Buhl

Aarhus Universitet

T Wahlberg

Skaraborgs Sjukhus

Rune Wejstål

Göteborgs universitet

Johan Westin

Göteborgs universitet

Gunnar Norkrans

Göteborgs universitet

Journal of Viral Hepatitis

1352-0504 (ISSN) 1365-2893 (eISSN)

Vol. 18 6 400-407

Ämneskategorier

Mikrobiologi inom det medicinska området

DOI

10.1111/j.1365-2893.2010.01323.x

PubMed

20500548

Mer information

Senast uppdaterat

2021-01-05